This English version is intended to be a reference material for the convenience of users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Summary of investigation results

Fluvastatin sodium, Pravastatin sodium, Simvastatin, Atorvastatin calcium hydrate, Pitavastatin calcium hydrate, Rosuvastatin calcium, Amlodipine besilate/Atorvastatin calcium hydrate

October 18, 2016

Non-proprietary name

a. Fluvastatin sodium
b. Pravastatin sodium
c. Simvastatin
d. Atorvastatin calcium hydrate
e. Pitavastatin calcium hydrate
f. Rosuvastatin calcium
g. Amlodipine besilate/Atorvastatin calcium hydrate

Brand name (Marketing authorization holder)

a. Lochol Tablets 10 mg, 20 mg, 30 mg (Novartis Pharma K.K.), and the others
b. Mevalotin Tablets 5 mg, 10 mg, Mevalotin Fine Granules 0.5%, 1% (Daiichi Sankyo Co., Ltd.), and the others
c. Lipovas Tablets 5 mg, 10 mg, 20 mg (MSD K.K.), and the others
d. Lipitor Tablets 5 mg, 10 mg (Astellas Pharma Inc.), and the others
e. Livalo Tab. 1 mg, 2 mg, 4 mg, Livalo OD Tab. 1 mg, 2 mg, 4 mg (Kowa Company, Ltd.), and the others
f. Crestor Tablets 2.5 mg, 5 mg, Crestor OD Tablets 2.5 mg, 5 mg (AstraZeneca K.K.)
g. Caduet Combination Tablets No. 1, No. 2, No. 3, and No. 4 (Pfizer Japan Inc.), and the others

Indications

- a, d–f
  Hypercholesterolemia, familial hypercholesterolemia

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

- b, c
  Hyperlipidemia, familial hypercholesterolemia
- g
  This product is indicated for the following patients for whom treatment with both amlodipine and atorvastatin is appropriate:
  Patients with hypertension or angina pectoris, and concurrently with hypercholesterolemia or familial hypercholesterolemia

Summary of revision

1. Precautions with regard to immune-mediated necrotizing myopathy should be added in the Important Precautions section.
2. Precautions with regard to “immune-mediated necrotizing myopathy” should be added in the Clinically Significant Adverse Reactions section.

Background of the revision and investigation results

Cases of immune-mediated necrotizing myopathy have been reported in patients treated with these products both in Japan and overseas. Following an investigation result based on the opinions of expert advisors and the available evidence, the MHLW/PMDA concluded that revision of the package insert was necessary, though the Other Precautions section includes the description.

The number of reported adverse reactions and fatal cases in the last 3 fiscal years in Japan

The following cases associated with immune-mediated necrotizing myopathy have been reported after administration of the following products:

a. Fluvastatin sodium
   No cases have been reported.
b. Pravastatin sodium
   No cases have been reported.
c. Simvastatin
   No cases have been reported.
d. Atorvastatin calcium hydrate
   One case has been reported (for which a causal relationship to the product could not be ruled out). No fatality has been reported.

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

e. Pitavastatin calcium hydrate
   No cases have been reported.

f. Rosuvastatin calcium
   A total of 2 cases has been reported (including 1 case for which a causal relationship to the product could not be ruled out). No fatality has been reported.

g. Amlodipine besilate/Atorvastatin calcium hydrate
   No cases have been reported.

Pharmaceuticals and Medical Devices Agency
Office of Safety I
3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp